

Supplementary Table 1. Patient characteristics of patients without *EGFR* mutation or *ALK* rearrangement treated with durvalumab (n=27).

	Patients treated with durvalumab n=27	DE50^{High} n=10	DE50^{Low} n=17	p
Age				
Median (range)	62 (37–79)	60 (43–79)	71 (37–78)	0.17
Gender, n (%)				
Male	22 (81)	8 (80)	14 (82)	1.00
Female	5 (19)	2 (20)	3 (18)	
Smoking status, n (%)				
Never	2 (7)	1 (10)	1 (6)	1.00
Former/Current	25 (93)	9 (90)	16 (94)	
ECOG PS, n (%)				
0	14 (52)	5 (50)	9 (53)	1.00
1	13 (48)	5 (50)	8 (47)	
Stage, n (%)				
II	1 (3)	1 (10)	0 (0)	1.00 (II and III vs. Recurrence)
III	25 (94)	9 (90)	16 (94)	
Recurrence	1 (13)	0 (0)	1 (6)	
PD-L1 expression, n (%)				
<1%	6 (24)	2 (22)	4 (25)	-
1-49%	3 (12)	1 (11)	2 (13)	
≥50%	16 (64)	6 (67)	10 (62)	
Unknown	2	1	1	
Histology, n (%)				
Sq	8 (30)	4 (40)	4 (24)	0.41
Non-Sq	19 (70)	6 (60)	13 (76)	
Durvalumab Treatment				
Completed full year	13 (48)	7 (70)	6 (35)	-
PD stopped	8 (30)	0 (0)	8 (47)	
IrAE stopped	5 (19)	2 (20)	3 (18)	
other	1 (3)	1 (10)	0 (0)	

ECOG PS, Eastern Cooperative Oncology Group performance status; Sq, Squamous cell carcinoma; PD-L1, programmed death-ligand 1; PD, progression disease; IrAE, Immune-related adverse events

Supplementary Table 2. Antibodies.

Antibodies	SOURCE	Clone
CD16	BD Biosciences	3G8
CD3	BD Biosciences	UCHT1
CD62L	Biolegend	DREG-56
Ki67	Biolegend	Ki-67
CD4	Biolegend	OKT4
CCR7	Biolegend	G043H7
CTLA-4 (CD152)	BD Biosciences	BNI3 (RUO)
B7-1 (CD80)	BD Biosciences	L307.4
CD28	Biolegend	CD28.8
Foxp3	eBioscience	236A/E7
CD56	BD Biosciences	B159
CD19	eBioscience	SJ25C1
PD-L1 (CD274)	BD Biosciences	MIH1
PD-1 (CD279)	Biolegend	EH12.2H7
CD45RA	Biolegend	HI100
CD8	Biolegend	SK1